| Literature DB >> 35049907 |
Senhua Chen1,2, Heng Guo1,2, Minghua Jiang1,2, Qilin Wu1,2, Jing Li1,2, Hongjie Shen1,2, Lan Liu1,2,3,4.
Abstract
Seven new xanthones, diaporthones A-G (1-7), together with 13 known analogues, including five mono- (8-14) and six dimeric xanthones (15-20), were obtained from the ascidian-derived fungus Diaporthe sp. SYSU-MS4722. Their planar structures were established by extensive spectroscopic analyses, including 1D and 2D NMR and high-resolution mass spectrometry (HR-ESIMS). The absolute configurations of 1-7 were clearly identified by X-ray crystallographic analysis and calculation of the ECD Spectra. Compounds 15-20 showed significant anti-inflammatory activity with IC50 values between 6.3 and 8.0 μM. In addition, dimeric xanthones (15-20) showed selective cytotoxicity against T98G cell lines with IC50 values ranging from 19.5 to 78.0 μM.Entities:
Keywords: Diaporthe sp.; anti-glioma activity; ascidian-derived fungus; xanthones
Mesh:
Substances:
Year: 2022 PMID: 35049907 PMCID: PMC8780748 DOI: 10.3390/md20010051
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–20.
1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data of 1 in CD3OD.
| No. | 1 | No. | 1 | ||
|---|---|---|---|---|---|
| 2 | 83.2, C | 8a | 159.4, C | ||
| 3 | 36.7, CH2 | 2.98, br s | 9 | 87.1, CH | 4.39, d (4.2) |
| 4 | 196.8, C | 10 | 29.6, CH | 2.85, m | |
| 4a | 107.2,C | 11 | 35.9, CH2 | 2.22, dd (21.6, 8.9) | |
| 5 | 161.4, C | 2.85, m | |||
| 6 | 106.9,CH | 6.40, d (8.3) | 12 | 177.3, C | |
| 7 | 138.1, CH | 7.36, t (8.3) | 13 | 61.5, CH2 | 3.76, s |
| 8 | 108.7, CH | 6.43, d (8.3) | 14 | 19.4, CH3 | 1.21, d (6.6) |
Figure 2Key 1H-1H COSY (red line) and HMBC (blue arrow) correlations of compounds 1–7.
Figure 3Key NOE (blue dash arrow) correlations of compounds 1, 3, and 4 (3D structures were generated by minimizing the energy using a molecular mechanics (MM2) computation by Chem3D).
Figure 4X-ray crystallographic analysis of 1 and 2.
Figure 5Experimental and predicted ECD spectra of 1 (a) and 3 (b) in MeOH.
1H (400 MHz) and 13C (100 MHz) NMR spectroscopic data of 2–4.
| No. | 2 a | 3 b | 4 a | |||
|---|---|---|---|---|---|---|
| 1 | 163.4, C | 163.1, C | 162.5, C | |||
| 2 | 109.7, CH | 6.44, dd (8.2, 0.9) | 108.8, CH | 6.36, d (8.7) | 109.2, CH | 6.41, dd (8.3, 1.0) |
| 3 | 139.0, CH | 7.39, t (8.3) | 138.6, CH | 7.36, t (8.3) | 138.8, CH | 7.34, t (8.3) |
| 4 | 109.6, CH | 6.55, d (8.2) | 108.2, CH | 6.39, d (8.8) | 109.2, CH | 6.41, dd (8.3, 1.0) |
| 4a | 159.8, C | 160.9, C | 161.1, C | |||
| 5 | 75.3, CH | 4.29, m | 73.9, CH | 4.74, d (6.3) | 71.6, CH | 3.90, d (2.1) |
| 5a | 76.2, C | 74.3, C | 83.5, C | |||
| 6 | 36.2, CH | 2.34, m | 140.1, C | 26.4, CH | 2.43, m | |
| 7 | 29.9, CH2 | 1.57, dt (14.8, 2.8) | 122.1, CH | 5.60, dt (4.6, 1.8) | 34.9, CH2 | 1.53, m |
| 2.43, m | 1.84, m | |||||
| 8 | 69.6, CH | 4.44, t (3.6) | 68.0, CH | 4.61, t (5.0) | 69.4, CH | 4.23, dt (4.7, 2.6) |
| 8a | 85.0, C | 86.9, C | 48.5, CH | 2.48, d (4.5) | ||
| 9 | 196.4, C | 197.3, C | 202.4, C | |||
| 9a | 108.6, C | 108.3, C | 111.3, C | |||
| 10 | 60.5, CH2 | 3.83, d (13.5) | 64.3, CH2 | 4.09, m | 63.2, CH2 | 3.72, d (12.0) |
| 4.28, m | 3.81, d (12.0) | |||||
| 11 | 20.7, CH3 | 1.32, d (7.8) | 19.3, CH3 | 1.84, d (1.4) | 18.0, CH3 | 1.06, d (7.0) |
| 1-OH | 11.26, s | |||||
| 5-OH | 4.84, d (6.6) | |||||
| 8-OH | 4.69, d (5.1) | |||||
| 8a-OH | 5.43, s | |||||
| 10-OH | 3.80, d (5.1) | |||||
a Spectra were recorded in CD3OD; b Spectra were recorded in acetone-d6.
Figure 6Experimental and predicted ECD spectra of 4 (a) and 5 (b) in MeOH.
1H (400 MHz) and 13C (100 MHz) NMR spectroscopic data of 5–7.
| No. | 5 a | 6 a | 7 b | |||
|---|---|---|---|---|---|---|
| 1 | 162.0, C | 164.4, C | 163.4, C | |||
| 2 | 108.1, CH | 6.42, d (8.2) | 108.5, CH | 6.52, d (8.2) | 109.7, CH | 6.48, dd, (8.3, 0.9) |
| 3 | 138.2, CH | 7.31, t (8.3) | 139.0, CH | 7.45, t (8.3) | 139.0, CH | 7.43, t, (8.3) |
| 4 | 110.5, CH | 6.52, d (8.3) | 110.9, CH | 6.54, d (8.2) | 109.7, CH | 6.59, dd, (8.3, 0.9) |
| 4a | 157.6, C | 161.2, C | 160.2, C | |||
| 5 | 70.3, CH | 5.72, s | 80.5, CH | 4.22, s | 74.5, CH | 4.28, m |
| 5a | 82.4, C | 78.1, C | 76.3, C | |||
| 6 | 27.8, CH | 2.39, m | 82.9, C | 29.2, CH | 2.25, m | |
| 7 | 33.5, CH2 | 2.43, m | 36.9, CH2 | 1.80, dt (15.2, 0.8)2.39, dd (15.2, 5.4) | 31.9, CH2 | 2.25, m2.06, m |
| 8 | 178.1, C | 71.1, CH | 4.47, dd (5.3, 0.9) | 68.5, CH | 4.40, t, (2.9) | |
| 8a | 101.0, C | 81.9, C | 85.4, C | |||
| 9 | 187.7, C | 195.6, C | 196.2, C | |||
| 9a | 106.7, C | 3.51, d (13.2) | 107.5, C | 108.6, C | ||
| 10 | 65.6, CH2 | 4.03, d (13.2) | 67.9, CH2 | 4.38, d (8.1)3.65, d (8.1) | 60.4, CH2 | 4.26, d (13.4)3.78, d (13.4) |
| 11 | 17.7, CH3 | 1.06, d (5.5) | 23.9, CH3 | 1.33, s | 18.1, CH3 | 1.12, d (6.7) |
| 12 | 170.8, C | |||||
| 13 | 21.0, CH3 | 2.09, s | ||||
| 14 | 162.0, C | |||||
a Spectra were recorded in CDCl3; b Spectra were recorded in CD3OD.
Figure 7X-ray crystallographic analysis of 6 and 7.
Figure 8Molecular packing properties of 7.
Figure 9Experimental and predicted ECD spectra of (+)- and (-)-7 (in MeOH).
Anti-glioma activity against T98G, U87MG, and U251 human cell lines and inhibition of NO production in LPS-induced RAW264.7 cells of compounds 11 and 14−20.
| Compounds | T98G (IC50, μM) | U87MG (IC50, μM) | U251 (IC50, μM) | Inhibition of NO |
|---|---|---|---|---|
|
| >100 | >100 | >100 | 41.4 |
|
| >100 | >100 | >100 | 32.2 |
|
| 23.8 | >100 | >100 | 6.3 |
|
| 19.5 | >100 | >100 | 7.5 |
|
| 57.6 | >100 | >100 | 6.3 |
|
| 34.6 | >100 | >100 | 7.6 |
|
| 74.1 | >100 | >100 | 8.0 |
|
| 78.2 | >100 | >100 | 7.8 |
| Temozolomide | 151 | 203 | 189 | - |
| Indomethacin | - | - | - | 35.8 |